Application of intravenous alfentanil combined with cyclophenol in hysteroscopic surgery

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400080232

Enrollment

Unknown

Registered

2024-01-24

Start date

2024-01-31

Completion date

Unknown

Last updated

2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulterine diseases

Interventions

Alfentanil 8 µg/kg group:Intravenous alfentanil

alfentanil 10 µg/kg group:Intravenous alfentanil

alfentanill 12 µg/Kg group:Intravenous alfentanil

alfenil 14 µg/Kg group :Intravenous alfentanil

sufentanil 0.15 µg/Kg group:Intravenous alfentanil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients without electrolyte disorders and infection, immune, endocrine system disease, recent period not taking cardiovascular drugs, non-steroidal anti-inflammatory drugs, hormones and anti-psychotic drugs.

Exclusion criteria

Exclusion criteria: Exclusive criteria: history of spontaneous delivery; Abnormal liver and kidney function; History of cardiopulmonary disease; Sleep apnea syndrome; Long-term use of diazepam and other drugs; Prolonged use of opioids; Opioid allergy.

Design outcomes

Primary

Measure	Time frame
ED50 of alfentanil,ED95 of alfentanil;Cumulative Probability;	—

Secondary

Measure	Time frame
Awakening Time;Dosage of cyclopofol;VAS score;	—

Countries

China

Contacts

Public ContactXu Lili

Women's Hospital School of Medicine Zhejiang University

704635871@qq.com+86 571 8999 2355

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026